Recently patented and promising ORL-1 ligands: where have we been and where are we going?

Author： Largent-Milnes Tally M Vanderah Todd W

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.20, Iss.3, 2010-03, pp. : 291-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tuberculosis: where are we going?

By Thwaites Guy

Clinical Medicine, Vol. 6, Iss. 6, 2006-12 ,pp. : 523-525

Royal College Of Physicians

Access to resources Recommend Favorite

Personalized medicine in oncology: where have we come from and where are we going?

By André Fabrice Ciccolini Joseph Spano Jean-Philippe Penault-Llorca Frédérique Mounier Nicolas Freyer Gilles Blay Jean-Yves Milano Gérard

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 931-939

Future Medicine

Access to resources Recommend Favorite

Chronic lymphocytic leukemia: where are we and where are we going?

By Ujjani Chaitra Cheson Bruce D

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 12, 2012-08 ,pp. : 1675-1677

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

By Boisdron-Celle Michèle

Pharmacogenomics, Vol. 13, Iss. 13, 2012-10 ,pp. : 1437-1439

Future Medicine

Access to resources Recommend Favorite

Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 10, 2010-07 ,pp. : 941-941

Bentham Science Publishers

Access to resources Recommend Favorite